OXB by the numbers
0+
Years of viral vector experience
0st
Commercial supplier of lentiviral vectors for a CAR-T therapy
0+
GMP batches released
0
GMP suites in three countries
~0
Client programmes
0%
Qualified assays and methods performed in-house
0+
Successful audits
0st
Company to treat patients in-vivo with lentiviral vector gene therapy
We offer end-to-end development and production capabilities for many viral vector types, from plasmid design and optimisation to clinical and commercial GMP manufacturing. These capabilities are supported by robust control systems, advanced analytical methods, and in-depth knowledge of global regulatory requirements.
About OXB
We are deeply committed to producing high-quality viral vectors, recognizing their crucial role in cell and gene therapies that bring hope to patients around the world. At OXB, we embrace this responsibility and understand that your success is our success.
Our platforms
Tech transferred-in
Alongside our own LentiVector™ and inAAVate™ platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.
Discover our latest news
OXB Secures New Four-Year Term Loan Facility with Oaktree
Up to $125 million Oaktree loan facility to support OXB’s global CDMO operations and growth strategy $60 million upfront to repay existing $50 million loan facility and for general corporate purposes Facility provides flexibility to draw down additional funds to support future business needs, if required Oxford, UK – 1 August 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has secured a new four-year loan facility of up to $125 million (the “New Oaktree Loan”), provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”), a long-term capital partner to OXB. The new facility will strengthen the Company’s financial foundation by refinancing its existing $50 million loan facility and providing financial flexibility to support OXB’s global CDMO operations and the delivery of its growth strategy. The New Oaktree Loan facility includes $60 million upfront funding available at close, which will be used to repay the existing $50 million four-year term loan facility with Oaktree (previously announced in October 2022) and for general corporate purposes. The facility also includes the option to draw down a further $25 million, subject to customary conditions, and an additional $40 million, subject to achieving certain revenue milestones – providing financial flexibility to support future business needs, if required. Terms of the New Oaktree Loan are broadly similar to the prior four-year loan facility and include standard and customary provisions relating to mandatory and voluntary prepayments, covenants, representations and warranties. The New Oaktree Loan will not amortise, with the full aggregate principal and outstanding amount being repayable on the final maturity date in 2029. Consistent with the terms of the existing facility, the New Oaktree Loan will be secured by substantially all of the assets of the Company and its wholly-owned subsidiaries and be guaranteed by the Company’s wholly-owned subsidiaries, with customary exceptions. Dr. Lucinda Crabtree, Chief Financial Officer of OXB, commented: “Refinancing this facility marks an important step in strengthening our financial agility as we continue to execute our growth strategy. Oaktree’s continued support reflects their long-standing confidence in OXB’s leading position in the CDMO viral vector market and enables us to remain focused on enhancing our capabilities, delivering on our strategic objectives and creating value for our clients and stakeholders.” Aman Kumar, Co-Portfolio Manager for Oaktree’s Life Sciences Lending platform, commented“We are delighted to extend our relationship with OXB through this debt refinancing. Over the course of our three previous investments, we have had an opportunity to witness first-hand the progress that the Company has made to establish itself as a global leader in the cell and gene therapy CDMO industry. We look forward to continuing to support the Company as it executes on its multi-vector, multi-site strategy.” Jefferies International Limited was the debt advisor to the Company, with King & Spalding LLP serving as legal counsel to OXB in connection with the refinancing. McDermott Will & Emery LLP served as legal counsel to Oaktree. -Ends- Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. About Oaktree Oaktree is a leader among global investment managers specializing in alternative investments, with $209 billion in assets under management as of June 30, 2025. The firm emphasizes an opportunistic, value-oriented, and risk-controlled approach to investments in credit, equity, and real estate. The firm has more than 1,200 employees and offices in 26 cities worldwide. For additional information, please visit Oaktree’s website at http://www.oaktreecapital.com/.
Half Year Trading Update; strong start to FY 2025 with full year guidance reiterated
Continued commercial, financial and operational momentum as OXB executes on its multi-vector, multi-site strategy H1 2025 revenues of £70-73 million, an increase of 38%-44% vs. £51 million at H1 2024 Commercial momentum accelerating, with £149 million new orders1 signed during H1 2025, more than double the £56 million orders signed during H1 2024 Full year 2025 guidance (CC2) reiterated: £160-170 million in revenues and low single digit operating EBITDA3 profitability Over £165 million of 2025 revenues contracted vs. £103 million at H1 2024 Strong order book reinforcing confidence in both full year 2025 and medium-term revenue growth Revenue backlog4 of £222 million at 30 June 2025 The Company will announce its H1 2025 interim results on 23 September 2025 with a Capital Markets Day scheduled for 15 October 2025 Oxford, UK – 28 July 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today provides a trading update for the six months ended 30 June 2025. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “With our multi-vector, multi-site model now fully in place, our strong operational and commercial progress continued in the first half of the year, reflecting both our execution capabilities and the growing trust in OXB as a leading cell and gene CDMO partner. Our order book has more than doubled year-on-year, including notable growth in late-stage programme activity, demonstrating strong demand for our services and providing long-term revenue visibility. As we expand capacity to meet this growing demand, we remain focused on operational excellence and cost discipline. With robust fundamentals in place and clear visibility into the second half of the year, we remain confident in our ability to deliver our full year guidance and achieve sustainable growth in 2025 and beyond.” Strong first half performance; full year guidance reiterated For the six months ended 30 June 2025, OXB expects to report revenues of approximately £70-73 million, representing an increase of 38%-44% over H1 2024 revenues of £51 million. The Company reiterates full year 2025 revenue guidance of £160-170 million (on a constant currency basis). Over £165 million of 2025 revenues are covered by contracted client orders, compared to £103 million for the same period last year. This provides clear visibility for the remainder of the year (subject to revenue performance obligations), with revenues weighted to the second half, in line with prior years. Second half revenue phasing includes an increase in manufacturing activity for clients preparing for commercial launch. With a continued focus on efficiency and a disciplined approach to cost management, the Company continues to expect low single digit Operating EBITDA profitability (on a constant currency basis) for the full year 2025. OXB’s cash position remains strong with gross cash of £53.9 million as of 30 June 2025. Late-stage lentiviral programme demand driving strong commercial momentum The contracted value of client orders signed during the first half of 2025 totalled approximately £149 million, compared to £56 million for the six months ended 30 June 2024. This includes signed orders from clients preparing for late-stage and commercial activities, providing strong visibility for the remainder of 2025 and 2026. Revenue backlog stood at approximately £222 million as at 30 June 2025, compared to approximately £150 million as at 31 December 2024. Demand for OXB’s CDMO services remains strong, with consistent conversion across all key vector types. The alignment of operations across the UK, the US and France is increasing efficiency and agility, allowing OXB to support clients across geographies and development stage. OXB is seeing increased client demand from existing and new clients, particularly among clients looking to accelerate execution of late-stage lentiviral programmes. AAV client activity has also continued to grow in line with expectations. Multi-vector, multi-site strategy delivering on plan OXB’s multi-vector, multi-site strategy continues to progress well, with lentiviral vector manufacturing capabilities now available across its UK, US and French sites. In June 2025, OXB completed the acquisition of the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio, Inc. The site is fully integrated into OXB’s global network and together with its UK and France operations, the Company is well positioned to provide global client support across all major vector types and development stages. Reflecting continued strong client demand for OXB’s services, the Company is proceeding with planned capacity management initiatives to accommodate current and expected growth. This comprises: i) an increase in GMP manufacturing capacity at OXB’s UK sites, to be achieved by refitting existing suites and modifying shift cadence, to be completed by H1 2026; and ii) expanding UK lab capacity for development services to support late-stage client programme activities, including increasing the use of automation. In addition, the Company has commenced transferring its AAV vector platform to its sites in France, providing a unified global operation focused on client-centric excellence. Process development and pilot manufacturing capabilities for AAV are now available for clients in France, with transfer of GMP capabilities targeted to be completed by the first half of 2026. Notice of Results and Capital Markets Day OXB will report its Interim Results for the six months ended 30 June 2025 on 23 September 2025. A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at RBC Capital Markets, 100 Bishopsgate, London, EC2N 4AA. The Company also announces it will host a Capital Markets Day on 15 October 2025. Further details, including the agenda and how to register, will be disclosed in due course. For details of other upcoming financial events, please refer to the Company’s investor calendar at https://oxb.com/investor-events/. 1 Contracted value of client orders represent the value of customer orders for which the customer has signed a financial commitment, whereby any changes to agreed values will be subject to either change orders, cancellation fees or the triggering of optional/contingent contractual clauses. 2 CC refers to Constant Currency, which refers to the equivalent growth based on the prior year exchange rates. 3 Operating EBITDA (Earnings Before Interest, Tax, Depreciation, Amortisation, Impairment, revaluation of investments and assets at fair value through profit and loss and share based payments). 4 Revenue backlog represents the ordered gross value of CDMO revenues available to earn. The value of customer orders included in revenue backlog only includes the value of work for which the customer has signed a financial commitment for OXB to undertake, whereby any changes to agreed values will be subject to change orders, cancellation fees or the triggering of optional/contingent contractual clauses. Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
OXB completes acquisition of remaining stake in US subsidiary
Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 April 2025, OXB US Inc., OXB’s wholly owned US subsidiary, exercised its call option on 1 March 2025 to acquire the final 10% interest in OXB US LLC from Q32. The stake was originally held by Homology Medicines, Inc (Homology), which merged with Q32 in 2024. The transfer of Q32’s 10% holding to OXB US Inc., means that OXB US LLC is now wholly owned by OXB. OXB US LLC was originally established in Bedford, MA, in 2022, as an AAV manufacturing and innovation business. The facility has since been fully integrated into OXB’s global network, successfully completing the tech transfer of its lentiviral platform to the site in 2024. Spanning 96,000 ft², the site offers lentiviral and AAV vector capabilities and has supported the onboarding of multiple new programmes in the US, as part of OXB’s global cell and gene therapy development and manufacturing network. Dr Frank Mathias, Chief Executive Officer of OXB, commented: “The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing – a critical enabler of the expanding cell and gene therapy market. “Our presence in the US, alongside our existing sites in the UK and France, gives clients access to deep expertise across AAV and lentiviral-based therapies. Through OXB’s network, we are able to support clients globally across all key vector types – from early-stage development through to commercialisation.” Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
OXB Named as one of Europe’s Most Innovative Companies by Fortune
Oxford, UK – 16 June 2025: OXB has been ranked 34th out of 300 organisations in Fortune’s list of Europe’s most innovative companies, a recognition that underscores the company’s leadership in cell and gene therapy innovation. The list, compiled based on evaluations by industry experts and employees, highlights businesses delivering meaningful innovation across sectors including life sciences, technology and manufacturing. A leading cell and gene therapy contract development and manufacturing organisation (CDMO) with 30 years of viral vector expertise, OXB currently supports 48 client programmes across the UK, France and US. It is one of just 22 UK-based and one of only four healthcare organisations to earn a place on the prestigious list. OXB’s innovation strategy is committed to helping clients overcome the complex landscape of developing and manufacturing cell and gene therapies. The company continues to advance its proprietary inAAVate™ and LentiVector™ platforms, for AAV and lentiviral vectors respectively, delivering greater scalability, performance and process efficiency. “Being named one of Europe’s most innovative companies is a powerful affirmation of our mission,” said Dr. Frank Mathias, Chief Executive Officer, OXB. “Innovation at OXB is purpose-driven, focused on empowering our clients to bring transformative cell and gene therapies to patients. This recognition reflects the dedication of our teams across the globe who consistently push the boundaries of what’s possible in advanced therapy development and manufacturing.” Read more on Fortune’s website.
AGM Update
Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK The Company remains on track to deliver the outlook set out in the Preliminary Results published on 9 April 2025 Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025 to date, as it continues to provide viral vector manufacturing services to a diversified portfolio of clients. The Company remains on track to deliver the outlook set out in the Preliminary Results for the year ended 31 December 2024, published on 9 April 2025. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “We have delivered strong operational performance so far in the first half of the year, reflecting disciplined execution across our global sites and sustained commercial momentum. The Company reiterates its financial guidance today and remains focused on supporting clients across all stages of development. OXB remains confident in its near and medium-term targets as set out earlier this year.” A corporate presentation will be given at the AGM by Dr. Frank Mathias, Chief Executive Officer and Dr. Lucinda Crabtree, Chief Financial Officer of OXB. No new material information will be disclosed. For details of upcoming financial events, please refer to the Company’s investor calendar at https://oxb.com/investor-events/. Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
OXB Highlights the Launch of its Innovation and Technology Excellence Board
Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will advise OXB on technology priorities, innovation opportunities and emerging trends that support the Company’s growth as a pure-play CDMO. The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing innovative technologies. This strategic insight will allow OXB to further enhance its value proposition to clients, while strengthening its market-leading position in the cell and gene therapy space. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “The Innovation and Technology Excellence Board marks a key step in OXB’s evolution as a pure-play CDMO focused on delivering best-in-class innovation for our clients. By bringing together some of the most respected voices in cell and gene therapy and biomanufacturing, we are creating a structure that will help us stay ahead of scientific and technological change, improve the way we work, and ultimately help our clients bring transformative therapies to patients.” Professor Dame Kay Davies DPhil FRS, Chair of OXB’s Innovation and Technology Excellence Board, added: “Cell and gene therapy continues to evolve quickly, and staying on top of that progress requires both scientific depth and external perspective. ITEB brings together a range of expertise to help OXB focus its innovation where it matters most: improving the way treatments are developed, manufactured and delivered. Our goal is to ensure that innovation leads to practical advances for OXB’s clients and better outcomes for patients.” Founding members of OXB’s Innovation and Technology Excellence Board are: Prof. Dame Kay Davies DPhil FRS (ITEB Committee Chair and Senior Independent Non-Executive Director of OXB) is among the most respected figures in human genetics, known for her research into the molecular basis of neuromuscular and neurological disease. She is Emeritus Dr. Lee’s Professor of Anatomy and Co-Director of the MDUK Oxford Neuromuscular Centre at the University of Oxford. Prof. Davies sits on the boards of UCB S.A. and Thomas White Oxford Ltd, she co-founded Summit Therapeutics plc and served as Deputy Chair of the Wellcome Trust (2013–2017). Prof. Uwe Buecheler, PhD, is a leading molecular biologist and biopharmaceutical executive with over 30 years of industry experience. He previously served as Head of the Biopharma Business Unit at Boehringer Ingelheim, overseeing global operations and the launch of more than 30 biologics. He is currently a Member of Supervisory Boards of Biotech companies and Non-Executive Director of BioPhorum, a company driving progress and fostering collaboration within the biopharmaceutical industry. He also chairs the Biopharma Cluster South Germany and advises biotech companies on CMC development and biomanufacturing strategy. Prof. Bruce Levine, PhD, is the Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania. He is co-inventor of Kymriah, the first FDA-approved CAR T cell therapy for leukaemia and lymphoma and has led pioneering first-in-human trials in cell and gene therapy. He is a co-founder of Tmunity and Capstan Therapeutics, holds over 30 US patents and has published more than 200 scientific papers. He is a Past President of the International Society for Cell and Gene Therapy and serves on the board of the Alliance for Cancer Gene Therapy. Prof. Axel Schambach, MD, PhD, is Director of the Institute of Experimental Hematology and Professor for Gene Modification of Somatic Cells at Hannover Medical School. His research focuses on the molecular pathophysiology of inborn and acquired diseases, with an emphasis on developing innovative gene therapy strategies, including novel vector systems and genome editing tools. He has received prestigious European grants for his pioneering work on gene therapies for hearing loss and is recognised for advancing precision genome editing and translational gene therapy. Prof. Schambach has contributed to a number of cell and gene therapy clinical trials. Prof. Luk Vandenberghe, PhD, is the Grousbeck Associate Professor in Gene Therapy at Harvard Medical School and Director of the Grousbeck Gene Therapy Center at Mass Eye and Ear and Mass General Brigham. A pioneer in AAV gene therapy, he co-invented AAV9 and has advanced novel vector technologies for treating neurosensory and other disorders. He has co-founded GenSight Biologics, Akouos, Affinia Therapeutics and the non-profit Odylia Therapeutics. Prof. Vandenberghe holds over 30 patents with more than 100 peer-reviewed publications in gene therapy research. Dr. Heather Preston (Observer and Independent Non-Executive Director of OXB) has over 30 years of experience in healthcare as a scientist, physician and management consultant and has been an investor in life sciences and biotechnology for more than 20 years. Over the course of her career, Dr. Preston has also served as a director on the boards of Oxford Science Enterprises plc, Karuna Pharmaceuticals and Akouos Inc. Dr. Preston also sits on the boards of Oxford Nanopore Technologies plc and Aligos Therapeutics, a Nasdaq-listed company. In addition, she is a Senior Advisor to TPG Biotech. Dr. Preston holds a degree in Medicine from the University of Oxford. The following members of OXB’s senior leadership team also sit on the Innovation and Technology Excellence Board: Dr. Frank Mathias (Chief Executive Officer of OXB) brings over 30 years of leadership experience in the biopharmaceutical and CDMO sectors. Prior to joining OXB, Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias was CEO of Medigene AG, a publicly listed immuno-oncology company focusing on the development of T-cell-based cancer therapies. He is currently the Chairman of the Board of Directors of ArcticZymes Technologies ASA, a supplier of best-in-class enzyme technologies. Dr. Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen Deutschland GmbH, Servier Deutschland GmbH and Hoechst AG and, in 2019, was awarded the title of “EY Entrepreneur of the Year” in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University. Thierry Cournez (Chief Operating Officer of OXB) has extensive experience in Sales, Marketing and GMP/GLP operations, with broad industry knowledge in the life science, biopharma and CDMO ecosystems. Prior to joining OXB, he served as Vice President of Global Testing Operations Bioreliance® at Merck Life Science, where he successfully managed large capacity expansion projects and held international responsibility for contract testing operations across the US, UK, Singapore and China. Prior to this, in his role as Vice President of End-to-End Bioprocessing Solutions, Mr. Cournez built and developed Merck Life Science’s End-to-End Promise Venture business unit, which involved the delivery and implementation of CDMO solutions for biopharma clients. Mr. Cournez holds an Engineer’s Degree in Biochemistry and Molecular Biology from INSA, Lyon, alongside a Master’s of Science in Molecular Biology from Paris VI University. Dr. Kyriacos Mitrophanous (Chief Innovation Officer of OXB) has over 30 years of lentiviral vector experience covering a range of technical disciplines, including the development of cell and gene therapies, delivery platform technologies, bioprocessing and analytics. Dr. Mitrophanous is a recognised world-class expert in the field, a named inventor on numerous lentiviral vector patents and an author of a number of key papers. In his current role, he is responsible for all aspects regarding client focussed innovation. He holds a PhD in Molecular Biology from University College London and has conducted post-doctoral research at the University of Oxford. Dr. Sébastien Ribault (Chief Business Officer of OXB) has over 25 years of experience across the biotechnology industry and CDMO space. Dr. Ribault was previously at Merck Life Science where he was Vice President & Head of Biologics and Viral Vector CDMO, leading Merck’s CDMO expansion project, establishing the Services business case and helping to establish the Life Science Services business unit. Prior to his 17 years with Merck Life Science, Dr. Ribault was a Gene Therapy Development Scientist at Transgene and Head of the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular Biology from the University of Strasbourg. Enquiries: OXB: Dr. Kyriacos Mitrophanous, Chief Innovation Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Oxford, UK – 8 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will exhibit at Booth #1611, where delegates can meet OXB’s team of viral vector experts and explore its development and manufacturing capabilities across lentiviral, AAV and other viral vector types. OXB will also contribute to the scientific programme through an industry-sponsored symposium, five poster presentations, and two oral presentations. Industry-Sponsored Symposium Accelerate Time to Clinic: A Process and Analytics Platform Approach Speaker: Ify Iwuchukwu, PhD, Vice President, Development Services, Head of Process and Analytical Development Date: Tuesday, 13 May 2025 Time: 14:00–14:30 CDT Location: Room 391–392 Poster Presentations The 3 Rs of Replication-Competent Lentivirus (RCL) Formation Risk: Real, Rare, or Artificial? Presenter: Dan Farley, PhD Date: Wednesday, 14 May 2025 Time: 17:30–19:30 CDT Location: Hall I2 Enhancing Titers of Therapeutic Lentiviral Vectors using PKC Agonists Presenter: André Raposo, PhD Date: Wednesday, 14 May 2025 Time: 17:30–19:30 CDT Location: Hall I2 Optimising the Production of the 4th Generation Lentiviral Vector (LV) TetraVecta™ System: Towards Plug-and-Play LV Manufacturing Presenter: Dan Farley, PhD Date: Wednesday, 14 May 2025 Time: 17:30–19:30 CDT Location: Hall I2 The Impact of Individual Helper Genes on AAV Productivity Presenter: Katrina Costa-Grant Date: Thursday, 15 May 2025 Time: 17:30–19:30 CDT Location: Hall I2 Evaluation of Salt-Tolerant Endonucleases for Lentiviral Vector Purification Presenter: Alice Oliveira Aguiar Date: Thursday, 15 May 2025 Time: 17:30–19:30 CDT Location: Hall I2 Oral Presentations Enhancing Upstream Processes for High-Yield, High-Quality AAV Vector Production Using a Novel In-House Cell Line Presenter: Dicky Gilmore Date: Friday, 16 May 2025 Time: 15:45–16:00 CDT Location: New Orleans Theater C Diving Deeper: Using a SYBR Gold Capsid Ejection Assay as an Orthogonal Method of Measuring Potency and VP1 Deamidation in AAV9 Drug Product Samples Presenter: Michaela Duffy Date: Friday, 16 May 2025 Time: 17:00–17:15 CDT Location: Room 288–290 Further information on OXB’s participation at ASGCT 2025 is available at www.asgct.org. Enquiries: OXB: Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
2025 Annual General Meeting notification
Oxford, UK – 28 April 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the 2024 Annual report and accounts are being sent to shareholders today. These documents are available on the “Investors” section of the Group’s website at www.oxb.com. In accordance with UK Listing rule 14.3.6R, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The Company intends to hold its AGM on Wednesday 11 June 2025 at its offices at Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m. Enquiries: OXB: Natalie Walter, Company Secretary – T: +44 (0) 1865 783 000 / E: cosec@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.